ScienceDaily (Oct. 20, 2008) — In a randomized controlled trial Angela Cheung and colleagues at the University of Toronto found that a high dose daily vitamin K1 supplement did not protect against age-related bone mineral density (BMD) decline. However, the findings also suggest that vitamin K1 may protect against fracture and cancer in postmenopausal women with osteopenia.

Dr. Cheung and colleagues randomized 440 postmenopausal women with osteopenia to receive either 5 mg of vitamin K1 or a placebo daily for two years. Two hundred and sixty one of these women continued their treatment for two more years to gather information about the long-term effects of vitamin K1 supplementation.

After two years and after four years, lower back and hip measurements of bone mineral density (BMD) had decreased by similar amounts in both the vitamin K and the placebo groups.

Over the four-year period, fewer women in the vitamin K group had fractures (9 versus 20 women in the placebo group) and fewer women had cancer (3 versus 12). Vitamin K supplementation was well tolerated over the four-year period and adverse health effects were similar in the two treatment groups, report the researchers. They emphasize that the study was not powered to examine fractures or cancers and the numbers were small, therefore the findings must be interpreted with caution.

The researchers say that larger studies are needed to examine the effect of vitamin K1 on fractures and on cancer and, until these are done, high dose vitamin K1 supplementation should not be recommended for the prevention of osteoporosis.

In the US, 10 million people have osteoporosis and 18 million have osteopenia, a milder condition that precedes osteoporosis.

Story Source:

Adapted from materials provided by Public Library of Science, via EurekAlert!, a service of AAAS.

Journal Reference:

1. Cheung et al. Vitamin K Supplementation in Postmenopausal Women with Osteopenia (ECKO Trial): A Randomized Controlled Trial. PLoS Medicine, 2008; 5 (10): e196 DOI: 10.1371/journal.pmed.0050196

Related Stories

Monitoring Bone Density In Older Women Is Unnecessary And Potentially Misleading, Study Suggests (June 23, 2009) — Monitoring bone mineral density in post-menopausal women taking osteoporosis drugs (bisphosphonates) is unnecessary and potentially misleading, concludes a new ...  > read more

Calcium And Vitamin D Supplements Don't Affect Heart Disease Risk, Study Suggests (Feb. 21, 2007) — Calcium/vitamin D supplementation neither increased nor decreased heart disease and stroke risk in generally healthy postmenopausal women over seven years of use, according to a study published in ...  > read more

Chronic Kidney Disease Should Not Prevent Women From Taking The Osteoporosis Drug Raloxifene, Study Suggests (Apr. 9, 2008) — The osteoporosis drug raloxifene increases bone mineral density and reduces the risk of vertebral fractures among postmenopausal women with mild to moderate chronic kidney disease, according to a new ...  > read more

Fight Osteoporosis: Bone Up On B12 (Apr. 23, 2005) — Women are about four times more likely than men to develop osteoporosis, or weak, porous bones. But a new study links vitamin B12 deficiency with low bone mineral density in men, and confirms ...  > read more

Search ScienceDaily

Sunscreen In A Pill